Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601595
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-15
Brief Title:
Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor TNF Inhibitors Treatment in Assiut University Hospital
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Spondyloarthropathy in Inflammatory Bowel Disease Patients and Evaluation of Its Response to TNF Inhibitors in Assiut University Hospital
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prevelance of axial spondylosis arthritis in inflammatory bowel disease and its RESPONSE to tumour necrosis factor TNF inhibitors TREATMENT
Detailed Description:
Inflammatory bowel disease IBD encompassing Crohns disease and ulcerative colitis represents a chronic inflammatory disease entity that mainly affects the gastrointestinal tract1 Extraintestinal manifestations however frequently occur and may involve different organ systems2 Among the most common extraintestinal manifestations are spondyloarthritis SpA here defined as ankylosing spondylitis psoriatic arthritis enteropathic arthritis reactive arthritis and undifferentiated spondyloarthritis diagnosis3 This group of rheumatic diseases share a similar clinical presentation with involvement of the spine sacroiliac joints peripheral arthritis and frequently also enthesitis4 Both IBD and SpA are also highly heritable diseases and genome-wide and family-based association studies have demonstrated evidence of a shared genetic basis between IBD and SpA5-6 Comorbidity with SpA has been associated with disability and decreased quality of life in IBD patients7 In some IBD patients these complications of SpA can lead to greater morbidity than the typical gastrointestinal symptoms for IBD8 Even though lower back pain is commonly reported by IBD patients with SpA early symptoms related to SpA may be mild and not always recognisable However an early diagnosis of SpA is important since a delayed diagnosis may potentially lead to a more severe disease course and poor treatment responses in patients with SpA9 Infliximab is a genetically constructed immunoglobulin IgG1 murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of tumor necrosis factor-α TNF-α Consequently it helps to decrease the biological activity of TNF-α 10 Neutralization of TNF-α has been suggested as a therapeutic strategy for patients with inflammatory bowel disease IBD rheumatoid arthritis RA spondyloarthropathy SpA and various other chronic inflammatory conditions 11
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None